The Natural History of PBC: Has It Changed?

 

 Buy Article Permissions and Reprints

ABSTRACT

The prognosis and natural history of primary biliary cirrhosis (PBC) have improved significantly during the last few decades. Patients are diagnosed at earlier stages, are more likely to be asymptomatic at diagnosis, and are more likely to receive medical treatment. The survival of asymptomatic patients is longer than the median survival of symptomatic patients. The natural history of PBC has been assessed in the presence of effective therapy, ursodeoxycholic acid (UDCA). Evidence suggests that UDCA delays histological progression in PBC and decreases the risk of development of esophageal varices. Survival of UDCA-treated patients is better than that of untreated patients and also is better than that predicted by the Mayo model. For patients in early stages of PBC, UDCA treatment may normalize survival. However, patients with stage III and IV PBC do not respond as well to UDCA. Therefore, there is a continued need for additional treatment in patients with advanced disease.

REFERENCES

• 1 Prince M I, James O F. The epidemiology of primary biliary cirrhosis.  Clin Liver Dis. 2003;  7 795-819
  CrossrefPubMedGoogle Scholar
• 2 MacMahon H E, Tannhauser S J. Xanthomatous biliary cirrhosis (a clinical syndrome).  Ann Intern Med. 1949;  30 121-131
  PubMedGoogle Scholar
• 3 Ahrens E J, Payne M, Kunkel H et al.. Primary biliary cirrhosis.  Medicine. 1950;  29 299-364
  PubMedGoogle Scholar
• 4 Sherlock S. Primary biliary cirrhosis (chronic intrahepatic cholestasis).  Gastroenterology. 1959;  31 574-582
  PubMedGoogle Scholar
• 5 Long R G, Scheurer P J, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis.  Gastroenterology. 1977;  72 1204-1207
  PubMedGoogle Scholar
• 6 Roll J, Boyer J L, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis.  N Engl J Med. 1983;  308 1-7
  PubMedGoogle Scholar
• 7 Balasubramaiam K, Grambsch P M, Wiesner R H et al.. Diminished survival in asymptomatic primary biliary cirrhosis: a prospective study.  Gastroenterology. 1990;  98 1567-1571
  PubMedGoogle Scholar
• 8 Mahl T C, Shockcor W, Boyer J L. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years.  J Hepatol. 1994;  20 707-713
  CrossrefPubMedGoogle Scholar
• 9 Pares A, Rodes J. Natural history of primary biliary cirrhosis.  Clin Liver Dis. 2003;  7 779-794
  CrossrefPubMedGoogle Scholar
• 10 Springer J, Cauch-Dudek K, O'Rourke K, Wanless I, Heathcote E J. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis.  Am J Gastroenterol. 1999;  94 47-53
  CrossrefPubMedGoogle Scholar
• 11 Prince M I, Chetwynd A, Craig W L et al.. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.  Gut. 2004;  53 860-870
  CrossrefPubMedGoogle Scholar
• 12 Christensen E, Neuberger J, Crowe J et al.. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final result of an international trial.  Gastroenterology. 1985;  89 1084-1091
  PubMedGoogle Scholar
• 13 Locke G R, Therneau T M, Ludwig J, Dickson E R, Lindor K D. Time course of histological progression in primary biliary cirrhosis.  Hepatology. 1996;  23 52-56
  PubMedGoogle Scholar
• 14 Angulo P, Batts K P, Therneau T M et al.. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.  Hepatology. 1999;  29 644-647
  CrossrefPubMedGoogle Scholar
• 15 Degott C, Zafrani E S, Callard P et al.. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.  Hepatology. 1999;  29 1007-1012
  CrossrefPubMedGoogle Scholar
• 16 Pares A, Caballeria L, Rodes J et al.. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial.  J Hepatol. 2000;  32 561-566
  CrossrefPubMedGoogle Scholar
• 17 Corpechot C, Carrat F, Bonnand A. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primay biliary cirrhosis.  Hepatology. 2000;  32 1196-1199
  CrossrefPubMedGoogle Scholar
• 18 Poupon R E, Lindor K D, Pares A et al.. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.  J Hepatol. 2003;  39 12-16
  CrossrefPubMedGoogle Scholar
• 19 Gores G J, Wiesner R H, Dickson E R et al.. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival.  Gastroenterology. 1989;  96 1552-1559
  PubMedGoogle Scholar
• 20 Takeshita E, Kumagi T, Matsui H et al.. Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis.  J Gastroenterol. 2003;  38 1060-1065
  CrossrefPubMedGoogle Scholar
• 21 Lindor K D, Jorgensen R A, Therneau T M et al.. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis.  Mayo Clin Proc. 1997;  72 1137-1140
  PubMedGoogle Scholar
• 22 Grambsch P M, Dickson E R, Kaplan M et al.. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability.  Hepatology. 1989;  10 846-850
  PubMedGoogle Scholar
• 23 Poupon R E, Lindor K D, Cauch-Dudek K et al.. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.  Gastroenterology. 1997;  113 884-890
  CrossrefPubMedGoogle Scholar
• 24 Lindor K D, Therneau T M, Jorgensen R A et al.. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.  Gastroenterology. 1996;  110 1515-1518
  PubMedGoogle Scholar
• 25 Corpechot C, Carrat F, Bahr A et al.. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.  Gastroenterology. 2005;  128 297-303
  CrossrefPubMedGoogle Scholar
• 26 Papatheodoridis G V, Hadziyannis E S, Deutsch M, Hadziyannis S J. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.  Am J Gastroenterol. 2002;  97 2063-2070
  CrossrefPubMedGoogle Scholar
• 27 Combes B, Luketic V A, Peters M G et al.. Prolonged follow-up of patients in the U.S. Multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis.  Am J Gastroenterol. 2004;  99 264-268
  CrossrefPubMedGoogle Scholar
• 28 Prince M, Chetwynd A, Newman W et al.. Patient survival and symptom progression in a large geographically based cohort of patients with PBC: Follow up for up to 28 years.  Gastroenterology. 2002;  123 1044-1051
  CrossrefPubMedGoogle Scholar
• 29 Goulis J, Leandor G, Burroughs A. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.  Lancet. 1999;  354 1053-1060
  CrossrefPubMedGoogle Scholar
• 30 Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis (Cochrane Review). In: The Cochrane Library, Issue 1 Oxford, United Kingdom; Update Software 2003
  Google Scholar
• 31 Leuschner M, Dietrich C F, You T et al.. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment.  Gut. 2000;  46 121-126
  CrossrefPubMedGoogle Scholar
• 32 Van Norstrand M D, Malinchoc M, Lindor K et al.. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression.  Hepatology. 1997;  25 6-11
  CrossrefPubMedGoogle Scholar

Young-Mee LeeM.D. 

Gastroenterology Division, Tufts-New England Medical Center

750 Washington Street, Boston, MA 02111

Email: ylee@tufts-nemc.org